Combination of miR-34a and let-7 suppressed p53-deficient tumor growth103 and demonstrated a synergic anti-proliferative effect with EGFR inhibitor erlotinib, but not other commonly used chemotherapeutics.104 MiR-34a also prevented HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells,105 suggesting a benefit of adjuvant miRNA-based therapy in p53-deficient NSCLC. Here, TP53 is linked to lung carcinoma.